NYSE$INSP

Inspire Medical Systems Inc. · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported a 77% year-over-year revenue increase, driven by increased utilization at existing sites and the addition of new implanting centers and sales territories.

Inspire Medical Systems reported strong third-quarter results with a 77% increase in revenue compared to the previous year, driven by increased utilization at existing sites and expansion of implanting centers and sales territories. The company is raising its full-year 2022 revenue guidance to $384 million to $388 million.

  • Generated revenue of $109.2 million, a 77% increase year-over-year.
  • Achieved a gross margin of 81.9%.
  • Activated 59 new centers in the U.S., bringing the total to 844.
  • Created 18 new U.S. sales territories, bringing the total to 209.

Headline financials

Total Revenue

$109M

Previous: $61.7M+77.0%
EPS (adj)

-$0.60

Previous: -$0.38-57.9%
Capital Expenditures

-$6.15M

Previous: -$4.14M-48.6%
Free Cash Flow

-$23M

Previous: -$14.5M-58.8%
Net Income

-$16.8M

Previous: -$10.3M-62.8%
Operating Income

-$17.2M

Previous: -$9.8M-75.5%
Gross Profit

$89.4M

Previous: $53.1M+68.5%
Cash & Equivalents

$418M

Previous: $210M+98.8%
Total Assets

$528M

Previous: $279M+89.1%
Stock-Based Comp

$14.6M

Previous: $6.81M+114.2%

Revenue & EPS history

Inspire · Revenue · Quarterly

$109M

Q3 2022+77%vs Q3 2021
Beat estimate in 15 of 15 quarters(100%)
ActualEstimate

Forward guidance

Inspire is increasing its full year 2022 revenue guidance to between $384 million to $388 million and is maintaining its full year 2022 gross margin guidance of 83% to 85%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+2.4%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+3.3%

Avg return

30 days after

69%

22 / 32 earnings

Positive

+34.4%

Q3 2020

Best reaction

-34.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-12.2%-19.2%-23.1%
Q4 2025-12.5%-11.5%-14.1%
Q3 2025+15.6%+11.0%+90.0%
Q1 2025+1.6%-4.7%-14.4%
Q4 2024+1.7%+2.6%-12.2%
Q3 2024+4.3%+3.1%+3.3%
Q2 2024+29.5%+32.8%+35.6%
Q1 2024-34.9%-33.1%-37.7%
Q4 2023-6.5%-9.8%-4.8%
Q3 2023-20.9%-23.5%-2.1%
Q2 2023-3.5%-3.7%-21.2%
Q1 2023+5.0%+5.8%+15.3%
Q4 2022+9.7%+7.9%-0.4%
Q3 2022+6.0%+6.4%+22.9%
Q2 2022+4.4%+4.0%-11.0%
Q1 2022-4.5%-19.8%-14.4%
Q4 2021+5.4%+0.6%-1.4%
Q3 2021+1.3%+4.1%-16.0%
Q2 2021+12.9%+14.4%+26.1%
Q1 2021-16.0%-17.4%-29.6%
Q4 2020+3.4%+4.1%-11.4%
Q3 2020+34.4%+40.7%+60.3%
Q2 2020+7.4%+3.5%+17.9%
Q1 2020+3.7%+6.2%+26.1%
Q4 2019+6.4%+7.7%-27.2%
Q3 2019+4.3%+4.8%+21.7%
Q2 2019+4.5%+1.9%+7.3%
Q1 2019-2.5%-5.7%-0.6%
Q4 2018+5.4%+5.0%-4.5%
Q3 2018+15.4%+1.8%-9.9%
Q2 2018-1.8%-0.1%+15.6%
Q1 2018+10.0%+6.4%+20.5%
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro